InsiderSignal.AI

InsiderSignal.ai

BBIO - Bridgebio Pharma, Inc.

Insider Sale by Kumar Neil (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Kumar Neil, serving as CEO at Bridgebio Pharma, Inc. (BBIO), sold 80,000 shares at $68.76 per share, for a total transaction value of $5,501,068.00. Following this transaction, Kumar Neil now holds 5,308,584 shares of BBIO.

This sale represents a 1.00% decrease in Kumar Neil's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, March 12, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 16, 2026, 4 days after the trade was made.

Bridgebio Pharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Kumar Neil

Kumar Neil

CEO

Neil Kumar, PhD, is the Founder and Chief Executive Officer of BridgeBio Pharma, Inc., a biopharmaceutical company dedicated to developing life-altering medicines for well-characterized genetic diseases using a 'hub-and-spoke' model for efficient drug development.[[1]](https://bbotx.com/team/neil-kumar-ph-d/)[[3]](https://milkeninstitute.org/events/global-conference-2025/speakers/neil-kumar)[[4]](https://timmermanreport.com/2025/11/building-a-rare-disease-company-neil-kumar-on-the-long-run/) He co-founded BridgeBio in 2015 and has led the company to achieve 18 INDs and three approved products in under 10 years, including the recent launch of Attruby for transthyretin amyloidosis with cardiomyopathy.[[7]](https://www.youtube.com/watch?v=b5q9n7Z2DSs)[[5]](https://www.biopharmadive.com/news/bridgebio-neil-kumar-attruby-ttr-amyloidosis-launch/737975/) Kumar recently traded BBIO shares, selling approximately 73,363 shares worth $6 million on January 8-9, 2026.[[9]](https://de.investing.com/news/insider-trading-news/bridgebio-pharma-ceo-kumar-verkauft-aktien-im-wert-von-6-mio--93CH-3297778) Prior to BridgeBio, Dr. Kumar served as a Principal at Third Rock Ventures, where he managed portfolio companies, focused on new company formation, and acted as interim VP of Business Development and Operations for MyoKardia.[[1]](https://bbotx.com/team/neil-kumar-ph-d/)[[2]](https://navirepharma.com/team-member/neil-kumar-ph-d-2/)[[3]](https://milkeninstitute.org/events/global-conference-2025/speakers/neil-kumar) Earlier, he was an Associate Principal at McKinsey & Company, developing strategies for pharmaceutical and medical device firms and leading personalized medicine initiatives.[[1]](https://bbotx.com/team/neil-kumar-ph-d/) He also founded GondolaBio, serving as Executive Chair, and sits on the board of BridgeBio Oncology Therapeutics.[[3]](https://milkeninstitute.org/events/global-conference-2025/speakers/neil-kumar)

View full insider profile →

Trade Price

$68.76

Quantity

80,000

Total Value

$5,501,068.00

Shares Owned

5,308,584

Trade Date

Thursday, March 12, 2026

6 days ago

SEC Filing Date

Monday, March 16, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Bridgebio Pharma, Inc.

Company Overview

No company information available
View news mentioning BBIO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4841054

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime